 | | Vol. 8.02 – 21 January, 2022 |
| |
|
|
| Researchers found that interleukin-37b transgenic mice were highly susceptible to colitis-associated colorectal cancer and suffered from dramatically increased tumor burdens in the colon.
[Signal Transduction and Targeted Therapy] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Genome-wide expression profiling, in vitro and in vivo experiments, revealed that timeless knockdown induced the activation of the epithelial-to-mesenchymal transition (EMT) program.
[Cell Death & Differentiation] |
|
|
|
| Investigators developed a chronic-injury model in human colonoid monolayers by repeated rounds of air-liquid interface and submerged culture.
[Cell Reports] |
|
|
|
| BEST4 is a member of the bestrophin protein family that plays a critical role in human intestinal epithelial cells. Scientists investigated the role and clinical significance of BEST4 in colorectal cancer.
[Oncogene] |
|
|
|
| HERC3 was indicated to inhibit the migration, invasion and metastasis of colorectal cancer in vitro and in vivo through transwell assays, wound healing assays and vivo experiments.
[Cell Death & Disease] |
|
|
|
| Scientists demonstrated that FTO, a key demethylase for RNA m6A modification, was up-regulated in gastric cancer tissues, especially in tissues with liver metastasis.
[Cell Death & Disease] |
|
|
|
| The authors analyzed the expression of 373 miRNAs and 12 deregulated metabolic genes in murine duodenal polyps and non-polyp-derived organoids.
[Oncogenesis] |
|
|
|
| Researchers showed that the expression of epididymal protein 3A (EDDM3A) was significantly upregulated in gastric cancer tissues and its upregulation correlated with poorer survival in patients with gastric cancer.
[Oncogenesis] |
|
|
|
| Scientists developed DNA methylation markers that recapitulated the densities of tumor-infiltrating lymphocytes in gastric carcinoma.
[Scientific Reports] |
|
|
|
| Researchers investigated the effects of cottonseed extracts on cell viability and gene expression in human colon cancer cells.
[Scientific Reports] |
|  |
|
|
|
| The authors review the current role for CTLA-4 inhibitors in early-stage resectable non-small cell lung cancer (NSCLC), unresectable stage III NSCLC, and in metastatic NSCLC.
[Current Oncology Reports] |
|
|
|
|
| Turning Point Therapeutics, Inc. announced that the company has received clearance from the FDA for the company’s IND application for the combination of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer.
[Turning Point Therapeutics, Inc.] |
|
|
|
|
|
|
|
| University of Oxford – Oxford, England, United Kingdom |
|
|
|
| University of North Dakota – Grand Forks, North Dakota, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Princess Margaret Cancer Centre – Toronto, Ontario, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
